EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

AAV Engineering for Improving Tropism to the Central Nervous System

Muhammad S Ghauri iD, Li Ou

Biology · 26.01.2023 · 12 (2) · 186

DOI: 10.3390/biology12020186 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biology, online erschienen am 26.01.2023. Verfasst von Muhammad S Ghauri und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, California University of Science and Medicine, Colton, CA 92324, USA. Die Arbeit wurde bisher 62-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adeno-associated virus (AAV) is a non-pathogenic virus that mainly infects primates with the help of adenoviruses. AAV is being widely used as a delivery vector for in vivo gene therapy, as evidenced by five currently approved drugs and more than 255 clinical trials across the world. Due to its relatively low immunogenicity and toxicity, sustained efficacy, and broad tropism, AAV holds great promise for treating many indications, including central nervous system (CNS), ocular, muscular, and liver diseases. However, low delivery efficiency, especially for the CNS due to the blood-brain barrier (BBB), remains a significant challenge for more clinical application of AAV gene therapy. Thus, there is an urgent need for utilizing AAV engineering to discover next-generation capsids with improved properties, e.g., enhanced BBB penetrance, lower immunogenicity, and higher packaging efficiency. AAV engineering methods, including directed evolution, rational design, and in silico design, have been developed, resulting in the discovery of novel capsids (e.g., PhP.B, B10, PAL1A/B/C). In this review, we discuss key studies that identified engineered CNS capsids and/or established methodological improvements. Further, we also discussed important issues that need to be addressed, including cross-species translatability, cell specificity, and modular engineering to improve multiple properties simultaneously.

Schlagwörter

Stichwörter der Autor:innen

AAVCNSblood-brain-barriercapsid engineeringdirected evolutionin silico

Autor:innen und Institutionen

  • School of Medicine, California University of Science and Medicine, Colton, CA 92324, USA.
  • Genemagic Biosciences, Media, PA 19086, USA.
  • Department of Pediatrics, University of Minnesota, Minneapolis, MN 55454, USA.

ORCID-Profile: Muhammad S Ghauri

Zitieren

APA

Ghauri, M. S., & Ou, L. (2023). AAV Engineering for Improving Tropism to the Central Nervous System. Biology, 12(2), 186. https://doi.org/10.3390/biology12020186

Vancouver

Ghauri MS, Ou L. AAV Engineering for Improving Tropism to the Central Nervous System. Biology. 2023;12(2):186. doi:10.3390/biology12020186

BibTeX
@article{Ghauri2023,
  author = {Ghauri, Muhammad S and Ou, Li},
  title = {AAV Engineering for Improving Tropism to the Central Nervous System},
  journal = {Biology},
  year = {2023},
  volume = {12},
  number = {2},
  pages = {186},
  doi = {10.3390/biology12020186}
}
Kostenlos starten →